Inside Drug Pricing

Stakeholders Press CMS For Clarity On IRA Small Biotech Exemption

By Gabrielle Wanneh / April 12, 2023 at 4:28 PM

Industry stakeholders are asking CMS to lay out a clear, flexible plan for how it will determine if drugs produced by small biotech companies may qualify for an exception in the Inflation Reduction Act that would prevent them from undergoing Medicare drug price negotiation for price applicability years 2026 through 2028.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Inside Drug Pricing

Stakeholders Press CMS For Clarity On IRA Small Biotech Exemption

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.